- Home
- PULM vs CANF Comparison
PULM vs CANF Comparison
Compare PULM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PULM | CANF |
|---|---|---|
| Founded | 2003 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 6.0M |
| IPO Year | 2013 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PULM | CANF |
|---|---|---|
| Price | $1.45 | $3.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 31.1K | 23.5K |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,910,000.00 | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5069.93 | N/A |
| 52 Week Low | $1.16 | $0.17 |
| 52 Week High | $7.20 | $10.40 |
Technical Indicators
Market Signals| Indicator | PULM | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 63.73 | 46.61 |
| Support Level | $1.21 | $2.87 |
| Resistance Level | $1.55 | $3.24 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 80.00 | 53.49 |
Price Performance
Historical ComparisonAbout PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.